|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Phillip Frost Ph.D.||Chairman & CEO||971,2k||N/D||1936|
|Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.||Vice Chairman & Chief Technical Officer||911,2k||N/D||1947|
|Mr. Adam E. Logal||Sr. VP & CFO||1,11M||N/D||1978|
|Mr. Steven D. Rubin||Exec. VP of Admin. & Director||821,2k||N/D||1960|
|Dr. Jon R. Cohen||Sr. VP & Director||1,74M||N/D||1955|
|Dr. Arie Gutman||Pres of API||N/D||N/D||1954|
|Mr. James DeMarco||Sr. VP of Pharmaceutical Sales||N/D||N/D||N/D|
|Dr. Akhtar Ashfaq||Sr. VP of Clinical R&D and Medical Affairs||N/D||N/D||N/D|
|Ms. Jane Pine Wood Esq., J.D.||Chief Legal Officer of Bio-Reference Laboratories||N/D||N/D||1963|
|Dr. David Okrongly Ph.D.||Pres of OPKO Diagnostics||N/D||N/D||1959|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
L'ISS Governance QualityScore di OPKO Health, Inc. al 26 settembre 2021 è 6. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 9; diritti degli azionisti: 3; retribuzione: 6.